Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients (MANON 02)

This study has been completed.
Sponsor:
Information provided by:
Objectif Recherche Vaccins SIDA
ClinicalTrials.gov Identifier:
NCT00219362
First received: September 16, 2005
Last updated: November 24, 2009
Last verified: November 2009

September 16, 2005
November 24, 2009
April 2004
November 2005   (final data collection date for primary outcome measure)
Change from baseline of the frequency of HIV-specific PBMC (CD4/CD8) at W24 (4 weeks after the last immunization)
Same as current
Complete list of historical versions of study NCT00219362 on ClinicalTrials.gov Archive Site
  • - Percentage of responders as defined by an increase of at least 0.7 log10 from baseline of the frequencies of HIV-specific PBMC and/or CD4 and/or CD8 T cells four weeks after the last immunization(W24) as measured by ELISpot IFNγ
  • - Change from baseline of the frequency of HIV-specific PBMC and/or CD4 and/or CD8 T cells at week 4, 6, 8, 12, 20 and 24 in the study arms as measured by ELISpot IFNγ
  • - Evaluation of the magnitude of CD4 and CD8 T cell response at W4, W6, W8, W12, W20, W24 in the study arms
  • - Evaluation of the immune responses, HIV-specific PBMC and/or CD4 and/or CD8 T cells at W48
  • - Percentage of patients who generate a primary immune response against the artificial pol/nef sequences present in the vaccine but not in the HIV strain
  • - Evaluation of the immune responses directed to vCP1452 in the study arms at all study point during the immunization phase
  • - Percentage of patients who do not reach the restart therapy criteria from W24 to W48
  • - Percentage of patients who remain off therapy at W48
  • - Evaluation of the safety and tolerability of the vCP1452
Same as current
Not Provided
Not Provided
 
Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients
A Phase II, Randomized, Placebo-controlled Study to Evaluate the Immunogenicity and the Safety of 2 Schedules of an Homologous Prime-boost With the ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients

Prior pilot studies have shown that four monthly injections of ALVAC-HIV (vCP1433) are immunogenic in 60% HIV-infected patients with a boosting effect obtained after 1 or 2 injections followed by a plateau or a decrease of these responses prior to interrupting therapy. The goal of the present study is to look for an improved vaccination schedule in terms of strength and duration of the HIV-specific immunity induced by the HIV-recombinant canary pox vector ALVAC-HIV (vCP1452) by testing a strategy of immunization involving a first series of two versus three monthly injections followed by a boost three months later.

Manon 02 is a phase II, multicentre, randomized, placebo-controlled study with 3 arms comprising 2 steps:

Step I : Immunization phase from W0 to W24, on HAART

The immunization will be administered by intramuscular injection :

Arm A: one injection of vCP1452 at W0, W4, W8 and W20 + HAART, for a total of 4 injections Arm B: one injection of vCP1452 at W4, W8 and W20 + HAART, for a total of 3 injections Arm C: one injection of placebo at W0, W4, W8 and W20 + HAART, for a total of 4 injections or at W4, W8 and W20 + HAART, for a total of 3 injections

Step II: Post immunization phase from W24 to W48, off HAART

Discontinuation of antiretroviral therapy (ARV) from W24 to W48 :

The ARV treatment interruption will be proposed at W24, 4 weeks after the last immunization, to patient who had completed their immunization phase and have CD4 cell counts > 350 cells/mm3 and HIV plasma RNA < 400 cp/ml.

In order to be able to evaluate the capacity of the immune response to reduce the viral replication, a period of 16 weeks of interruption is recommended from W24 to W40.

Resumption of antiretroviral therapy :

From W24 to W40 : During this 16 weeks period, in case of a decline of CD4 cell counts below 250 cells/mm3 or of a loss of CD4 greater than 50% of the baseline value, HAART will be restarted.

From W40 to W48 : HAART should be reintroduced if HIV-1 RNA levels > 50 000 cp/ml on 2 consecutive measurements at two weeks interval even if the CD4 counts are above 250 cells/mm3.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
HIV Infection
  • Biological: one injection of vCP1452 at W0, W4, W8 and W20
  • Biological: one injection of vCP1452 at W4, W8 and W20
  • Biological: one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20
  • Experimental: ALVAC-HIV 4 injections
    Arm A: injection of ALVAC-HIV(vCP1452) for a total of 4 injections (W0, W4, W8, W20)
    Intervention: Biological: one injection of vCP1452 at W0, W4, W8 and W20
  • Experimental: ALVAC-HIV 3 injections
    Arm B: injection of ALVAC-HIV(vCP1452) for a total of injections (W4, W8, W20)
    Intervention: Biological: one injection of vCP1452 at W4, W8 and W20
  • Placebo Comparator: Placebo - 4 injections
    Arm C1: injection of placebo for a total of 4 injections (W0, W4, W8, W20)
    Intervention: Biological: one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20
  • Placebo Comparator: Placebo - 3 injections
    Arm C2: injection of placebo for a total of 3 injections (W4, W8, W20)
    Intervention: Biological: one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
65
September 2006
November 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Documented HIV infection
  • under potent antiretroviral therapy for more than 6 months
  • with entry CD4+ counts > 350 cells/mm3 for at least 1 year
  • plasma HIV RNA < 400 cp/ml for at least the last 6 months
  • Contraception needed for women

Exclusion Criteria:

  • Antiretroviral therapy started with CD4 cell count > 400/mm3
  • Patients treated at time of primary HIV infection
  • Patient with past AIDS defining event
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Spain,   Germany,   United States,   France
 
NCT00219362
ORVACS 002
No
Pr Christine KATLAMA, Objectif Recherche Vaccins SIDA
Objectif Recherche Vaccins SIDA
Not Provided
Study Chair: Christine Katlama, MD Services des maladies infectieuses et tropicales, Hopital de la Pitié-Salpétrière, Université Pierre et Marie Curie, INSERM U720
Objectif Recherche Vaccins SIDA
November 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP